MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER⁺ Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MAGI1 functions as a tumor suppressor in estrogen receptor-positive (ER+) breast cancer (BC).
• Loss of MAGI1 is associated with a more aggressive BC phenotype.
• Understanding MAGI1's role is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the molecular pathways and cellular events influenced by MAGI1 loss in ER+ BC.
• To identify potential therapeutic targets in BC patients with low MAGI1 expression.

Main Methods:

• MAGI1 gene deletion in MCF7 ER+ BC cells.
• RNA sequencing and transcriptome analysis.
• In vitro functional experiments, including response to DNA damaging agents and pathway inhibitors.
• Analysis of human BC patient transcriptomic data.

Main Results:

• MAGI1 loss affects estrogen signaling, cell cycle, and DNA damage response pathways.
• MAGI1-deficient cells exhibit enhanced quiescence/senescence and altered AKT/MAPK signaling.
• MAGI1-deficient cells show reduced DNA repair protein expression and increased sensitivity to PARP1 inhibition.
• PI3K/AKT inhibitors restored DNA repair proteins and sensitized cells to fulvestrant.
• Low MAGI1 levels in patients correlate with higher tumor mutational burden and homologous recombination deficiency.
• MAGI1 expression inversely correlates with PI3K/AKT and MAPK signaling.

Conclusions:

• MAGI1 plays a significant role in regulating BC aggressiveness and response to therapy.
• Targeting PI3K/AKT/MAPK pathways or exploiting PARP1 inhibition may benefit BC patients with low MAGI1.
• HDACs are identified as regulators of MAGI1 expression, suggesting further therapeutic avenues.